Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To The Editor: Dr Freemantle and colleagues1 discussed the pros and cons of composite end points
in clinical trials and the difficulties in interpreting results when using
them. They argued that composite end points can be used to gain statistical
power or when there is uncertainty about which single end point to choose.
We would like to add a third reason: to be able to define a summary measure
for drug efficacy.
van Leth F, Lange JMA. Use of Composite End Points to Measure Clinical Events—Reply. JAMA. 2003;290(11):1456–1457. doi:10.1001/jama.290.11.1456-a
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: